more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$16.57 USD

-0.03 (-0.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock

by Zacks Equity Research Published on March 17,2020

Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PCRXNegative Net Change

medical

Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research Published on March 13,2020

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

PCRXNegative Net Change

The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra

by Zacks Equity Research Published on March 13,2020

The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra

consumer-discretionary

PCRX or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on March 13,2020

PCRX vs. ZTS: Which Stock Is the Better Value Option?

5 Best Stocks to Buy in a Coronavirus-Led Bear Market

by Tirthankar Chakraborty Published on March 12,2020

The period of a typical bear market has a propensity to be pretty lengthy. On average, bear market for the Dow and the S&P 500 lasts 206 and 146 trading days, respectively.

Why Pacira (PCRX) Could Be an Impressive Growth Stock

by Zacks Equity Research Published on March 10,2020

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)

PCRXNegative Net Change

medical

The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group

by Zacks Equity Research Published on March 05,2020

The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group

Coronavirus Triggers Rate Cut: Stocks That Can Defy Market Fall

by Supriyo Bose Published on March 04,2020

Amid the doom and gloom, we have cherry picked four stocks that possess potential to perform well in the long run.

Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss

by Zacks Equity Research Published on February 28,2020

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

3 Reasons Why Pacira (PCRX) Is a Great Growth Stock

by Zacks Equity Research Published on February 26,2020

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

PCRXNegative Net Change

PCRX vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on February 26,2020

PCRX vs. ZTS: Which Stock Is the Better Value Option?

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line

by Zacks Equity Research Published on February 21,2020

Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.

pharmaceuticals

Top Ranked Momentum Stocks to Buy for February 21st

by Zacks Equity Research Published on February 21,2020

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st

Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss

by Zacks Equity Research Published on February 20,2020

Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.

3 Top-Ranked Stocks Poised for an Earnings Beat

by Sanghamitra Saha Published on February 19,2020

Count on these top-ranked stocks that are likely to beat earnings estimates in their next releases.

Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research Published on February 13,2020

Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.

pharmaceuticals

FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA

by Zacks Equity Research Published on February 12,2020

The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.